Modality
Gene Editing
MOA
CD3xCD20
Target
VEGF
Pathway
DDR
OCDT2DCKD
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ May 2028
Phase 1Current
NCT05026679
1,292 pts·OCD
2018-05→TBD·Terminated
NCT04411167
247 pts·CKD
2019-07→2028-05·Terminated
1,539 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-212.1y awayPh2 Data· CKD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2028-05-21 · 2.1y away
CKD
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05026679 | Phase 1/2 | OCD | Terminated | 1292 | NT-proBNP |
| NCT04411167 | Phase 1/2 | CKD | Terminated | 247 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |